Cargando…
Biologics in severe uncontrolled chronic rhinosinusitis with nasal polyps: A bicentric experience
BACKGROUND AND AIM: The introduction of biologics in the management of chronic rhinosinusitis with nasal polyposis (CRSwNP) has allowed for new therapeutic options and dupilumab represents the first approved biological agent. Aim of this paper is to provide a bicentric study in a real-life setting o...
Autores principales: | Bellocchi, Gianluca, Loperfido, Antonella, Passali, Francesco Maria, Millarelli, Stefano, Velletrani, Gianluca, Perla, Marco, Di Michele, Loreta, Di Girolamo, Stefano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mattioli 1885
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644941/ https://www.ncbi.nlm.nih.gov/pubmed/37850768 http://dx.doi.org/10.23750/abm.v94i5.14745 |
Ejemplares similares
-
A Practical Clinical Protocol for Monitoring Patients with Severe Uncontrolled Chronic Rhinosinusitis with Nasal Polyposis Treated with Biologics
por: Millarelli, Stefano, et al.
Publicado: (2022) -
Biologics for severe uncontrolled chronic rhinosinusitis with nasal polyps: a change management approach. Consensus of the Joint Committee of Italian Society of Otorhinolaryngology on biologics in rhinology
por: De Corso, Eugenio, et al.
Publicado: (2021) -
The Impact of Antibiotics and Steroids on the Nasal Microbiome in Patients with Chronic Rhinosinusitis: A Systematic Review According to PICO Criteria
por: Loperfido, Antonella, et al.
Publicado: (2023) -
Practical recommendations for managing severe chronic rhinosinusitis with nasal polyps in the era of biologics
por: De Corso, Eugenio, et al.
Publicado: (2023) -
Dupilumab's Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life
por: Loperfido, Antonella, et al.
Publicado: (2023)